认识和联系Profil的专家

Ulrike Hövelmann 科学研究顾问 Ulrike是您在以下领域的联系伙伴: 糖尿病知识 临床试验知识 生物等效性 生物类似物

简介

Ulrike是一位医生，她在糖尿病临床研究方面拥有超过12年的专业知识，并拥有超过9年的临床护理背景。在Profil，她被任命为科学研究顾问。Ulrike于2003年加入Profil。她曾担任多个早期临床研究的首席研究员，尤其是采用葡萄糖钳夹技术进行的药效/药代动力学评估。

Ulrike是专业糖尿病组织EASD的活跃成员。 她还是《糖尿病，肥胖与代谢》的定期审稿人。

发表物

以下是Ulrikes的近期发表物:

• Hövelmann U, Reiter Y, Chullikana A, Liu M, Donnelly C, Lawrence T, Sengupta N, Cl G, Ranganna G, Barve A. Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study. DIABETES OBES METAB 2021 Aug 11. doi: 10.1111/dom.14519. Online ahead of print.

• Pieber TR, Aronson R, Hövelmann U, Willard J, Plum-Mörschel L, Knudsen KM, Bandak B, Tehranchi R.
  Dasiglucagon: A next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia. Results of phase 3 randomized double-blind clinical trial.
  DIABETES CARE 44: 1-7, 2021. 

• Linnebjerg H, Zhang Q, LaBell E, Dellva MA, Coutant DE, Hövelmann U, Plum-Mörschel L, Herbrand T, Leohr J.
  Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in younger adults and elderly patients with type 1 diabetes mellitus: A randomised controlled trial.
  CLIN PHARMACOKINET 2020 May 29. doi: 10.1007/s40262-020-0093-0. Online ahead of print

• Suico JG, Hövelmann U, Zhang S, Shen T, Bergman B, Sherr J, Zijlstra E, Frier BM, Plum-Mörschel L.
  Glucagon administration by nasal and intramuscular routes in adults with type 1 diabetes during insulin-induced hypoglycaemia: A randomised, open-label, crossover study.
  DIABETES THER 2020 Jun 8. doi: 10.1007/s13300-020-00845-7. Online ahead of print
• Hövelmann U, Braendholt Olsen M, Mouritzen U, Lamers D, Kronshage B, Heise T.
  Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
  DIABETES OBES METAB 2018 Oct 23. doi: 10.1111/dom.13562. (Epub ahead of print)
• Hövelmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B, Moller DV, Heise T.
  Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog.
  DIABETES CARE 2017 Dec 22. doi: 10.2337/dc17-1402. (Epub ahead of print)
• Heise T, Hövelmann U, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H.
  Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions: response to the commentary by Nuggehally R. Srinivas.
  CLIN DRUG INVEST 2017 Jun 8. doi: 10.1007/s40261-017-0539-7. (Epub ahead of print)
• Hövelmann U, Heise T, Nosek L, Sassenfeld B, Thomsen KM, Haahr H.
  Pharmacokinetic properties of fast-acting insulin aspart administered in different subcutaneous injection regions.
  CLIN DRUG INVESTIG 37: 503-509, 2017  
• Porksen N, Linnebjerg H, Garhyan P, Lam ECQ, Knadler MP, Jacober SJ, Hoevelmann U, Plum-Moerschel L, Watkins E, Gastaldelli A, Heise T.
  Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
  DIABETES OBES METAB 19: 482-488, 2017
• Heise T, Stender-Petersen K, Hövelmann U, Jacobsen JB, Nosek L, Zijlstra E, Haahr H.
  Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus.
  CLIN PHARMACOKINET 2016 Nov 22. doi: 10.1007/s40262-016-0473-5. (Epub ahead of print)
• Heise T, Hövelmann U, Zijlstra E, Stender-Petersen K, Jacobsen JB, Haahr H.
  A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus.
  DRUGS AGING 34 (1): 29-38, 2017
• Famulla S, Hövelmann U, Fischer A, Coester HV, Hermanski L, Kaltheuner M, Kaltheuner L, Heinemann L, Heise T, Hirsch L.
  Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action, and impaired postprandial glucose control.
  DIABETES CARE 39: 1486-1492, 2016
• Heise T, Hövelmann U, Nosek L, Hermanski L, Bottcher SG, Haahr H.
  Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
  EXPERT OPIN DRUG METAB TOXICOL 11: 1193-1201, 2015.
• Heise T, Hövelmann U, Brondsted L, Adrian CL, Nosek L, Haahr H.
  Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
  DIABETES OBES METAB 17: 682-688, 2015.

浏览Profil的发表物列表以查看我们的其他发表物。

主要成就及工作经验